Brokerages Set Alector, Inc. (NASDAQ:ALEC) PT at $14.00

Alector, Inc. (NASDAQ:ALEC) has been assigned an average rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $14.00.

A number of research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Alector in a report on Thursday, June 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Alector in a report on Thursday, June 20th.

Insider Buying and Selling

In related news, CEO Arnon Rosenthal sold 25,135 shares of Alector stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $4.80, for a total transaction of $120,648.00. Following the transaction, the chief executive officer now directly owns 1,975,245 shares of the company’s stock, valued at $9,481,176. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Arnon Rosenthal sold 25,135 shares of Alector stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $4.80, for a total transaction of $120,648.00. Following the transaction, the chief executive officer now directly owns 1,975,245 shares of the company’s stock, valued at $9,481,176. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Marc Grasso sold 6,920 shares of Alector stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $4.80, for a total value of $33,216.00. Following the transaction, the chief financial officer now directly owns 138,037 shares in the company, valued at $662,577.60. The disclosure for this sale can be found here. Insiders have sold a total of 40,095 shares of company stock valued at $192,456 over the last three months. Company insiders own 9.10% of the company’s stock.

Hedge Funds Weigh In On Alector

A number of institutional investors have recently bought and sold shares of ALEC. Vanguard Group Inc. increased its stake in Alector by 12.0% in the 1st quarter. Vanguard Group Inc. now owns 4,912,578 shares of the company’s stock worth $29,574,000 after purchasing an additional 526,037 shares in the last quarter. Acadian Asset Management LLC increased its stake in Alector by 211.6% in the 1st quarter. Acadian Asset Management LLC now owns 444,647 shares of the company’s stock worth $2,675,000 after purchasing an additional 301,936 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Alector in the 4th quarter worth about $1,920,000. Jacobs Levy Equity Management Inc. boosted its position in Alector by 16.2% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 922,799 shares of the company’s stock worth $5,555,000 after acquiring an additional 128,515 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new position in Alector during the 1st quarter valued at about $760,000. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Alector Stock Performance

ALEC stock opened at $6.49 on Monday. The stock has a market capitalization of $625.57 million, a price-to-earnings ratio of -4.70 and a beta of 0.73. Alector has a 1 year low of $3.66 and a 1 year high of $9.06. The stock’s fifty day moving average is $5.02 and its two-hundred day moving average is $5.68.

Alector (NASDAQ:ALEC) last posted its earnings results on Wednesday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.10. The company had revenue of $15.89 million for the quarter, compared to analysts’ expectations of $14.63 million. Alector had a negative return on equity of 71.80% and a negative net margin of 125.11%. As a group, analysts predict that Alector will post -1.93 EPS for the current fiscal year.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.